Liminal BioSciences: LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR

Liminal BioSciences Inc. announced that an amendment to the previously filed Schedule 13E-3 will be filed to address comments raised by the Securities and Exchange Commission in connection with the previously announced plan of arrangement involving the acquisition by Structured Alpha LP.